About Calliditas Therapeutics
Calliditas Therapeutics is a company based in Stockholm (Sweden) founded in 2004.. Calliditas Therapeutics has raised $44.83 million across 3 funding rounds from investors including Investinor and Industrifonden. The company has 40 employees as of December 31, 2022. Calliditas Therapeutics has completed 1 acquisition, including Genkyotex. Calliditas Therapeutics offers products and services including TARPEYO and Kinpeygo. Calliditas Therapeutics operates in a competitive market with competitors including Unicycive, Akebia Therapeutics, Alebund, Aurinia Pharmaceuticals and Renalys, among others.
- Headquarter Stockholm, Sweden
- Employees 40 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Calliditas Na Enterprises Inc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$44.83 M (USD)
in 3 rounds
-
Latest Funding Round
$21.96 M (USD), Series B
Jul 01, 2019
-
Investors
Investinor
& 1 more
-
Employee Count
40
as on Dec 31, 2022
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Calliditas Therapeutics
Calliditas Therapeutics offers a comprehensive portfolio of products and services, including TARPEYO and Kinpeygo. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treatment specifically designed for IgA nephropathy to manage rare kidney conditions.
Novel medication for rare diseases, focusing on renal and hepatic indications.
Unlock access to complete
Funding Insights of Calliditas Therapeutics
Calliditas Therapeutics has successfully raised a total of $44.83M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $21.96 million completed in July 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series B — $22.0M
-
First Round
First Round
(16 Oct 2013)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2019 | Amount | Series B - Calliditas Therapeutics | Valuation |
investors |
|
| Oct, 2015 | Amount | Debt – Conventional - Calliditas Therapeutics | Valuation |
investors |
|
| Oct, 2013 | Amount | Series A - Calliditas Therapeutics | Valuation | Investinor |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Calliditas Therapeutics
Calliditas Therapeutics has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Investinor and Industrifonden. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Investments in deep-tech, life sciences, and transformative tech are managed.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Calliditas Therapeutics
Calliditas Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Genkyotex. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Small molecule therapeutics are developed to selectively inhibit NOX enzymes.
|
2006 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Calliditas Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Calliditas Therapeutics Comparisons
Competitors of Calliditas Therapeutics
Calliditas Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Unicycive, Akebia Therapeutics, Alebund, Aurinia Pharmaceuticals and Renalys, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Small molecule therapies for kidney diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for kidney disease treatment are developed by Akebia Therapeutics.
|
|
| domain | founded_year | HQ Location |
Therapeutics for various kidney diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for autoimmune diseases are developed by Aurinia Pharmaceuticals.
|
|
| domain | founded_year | HQ Location |
Therapeutics for renal diseases are developed and launched by Renalys.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Calliditas Therapeutics
Frequently Asked Questions about Calliditas Therapeutics
When was Calliditas Therapeutics founded?
Calliditas Therapeutics was founded in 2004 and raised its 1st funding round 9 years after it was founded.
Where is Calliditas Therapeutics located?
Calliditas Therapeutics is headquartered in Stockholm, Sweden.
Who is the current CEO of Calliditas Therapeutics?
Renee Aguiar-Lucander is the current CEO of Calliditas Therapeutics.
Is Calliditas Therapeutics a funded company?
Calliditas Therapeutics is a funded company, having raised a total of $44.83M across 3 funding rounds to date. The company's 1st funding round was a Series A of $22.88M, raised on Oct 16, 2013.
How many employees does Calliditas Therapeutics have?
As of Dec 31, 2022, the latest employee count at Calliditas Therapeutics is 40.
What does Calliditas Therapeutics do?
Calliditas Therapeutics is involved in the development of small molecule-based drugs for inflammatory kidney diseases. Its leading candidate Nefecon is used in inflammatory kidney disease (IgA nephropathy) for the patients at risk of progressing to renal failure. It releases Budesonide, a Glucocorticosteroid, in the lower ileum and ascending colon of the gastrointestinal (GI) tract. The targeted release of the active ingredient to this region of the GI tract will bypass the systemic side effects of budesonide. The company has also discovered potential uses of this formulation for autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC).
Who are the top competitors of Calliditas Therapeutics?
Calliditas Therapeutics's top competitors include Akebia Therapeutics, Gennova and Alebund.
What products or services does Calliditas Therapeutics offer?
Calliditas Therapeutics offers TARPEYO and Kinpeygo.
How many acquisitions has Calliditas Therapeutics made?
Calliditas Therapeutics has made 1 acquisition, including Genkyotex.
Who are Calliditas Therapeutics's investors?
Calliditas Therapeutics has 2 investors. Key investors include Investinor, and Industrifonden.